The Entrepreneurship of Psychedelic Negativity: Psymposia, Trauma, Iatrogenic Harm, and Prohibition 2.0

This article outlines a skeptical appraisal of Psymposia, a small but influential self-appointed psychedelics “watchdog” organization based in the United States of America, which played a significant role in blocking regulatory approval for MDMA as a treatment for PTSD in 2024. Contextualized close analysis of its “Power Trip” podcast series, which focused on sexual abuse in the psychedelic community, interventions by its members during the FDA hearings and its allegations regarding a “Psychedelic Syndicate,” shows the group to have been an effective entrepreneur of psychedelic negativity. This article questions the group's sensationalist approach to trauma and the excessively narrow understanding of iatrogenic harm within which it presents its activism as harm-reduction, arguing that its opportunistic interventions have been conspiring objectively to produce Prohibition 2.0 by distributed anxiogenesis. Our research also shows that the group has benefited from over $400,000 USD in funding, most of it from undisclosed sources, some of which was likely used to fund “Comms” consultancy and buy media access. In conclusion, we reject the group's overall position and strategy as incoherent yet objectively damaging to substantive Left politics. The group's exaggerated influence is a reflection of the unusual conditions of knowledge production in psychedelic spaces over the last decade, especially in the online attentional economy. By naming the entrepreneurship of psychedelic negativity and by reflecting on the scope of iatrogenic harm and the meaning of harm reduction, this article aims to bring balance to ongoing cultural conversations around the medicalization of psychedelics, decriminalization, and the potential in these substances to catalyze socio-political transformation from the Left.